The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

NCT00154323 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis